Summary. This experimental study examined the effect of the antioxidant drug U-74389G on a rat model and particularly in a liver ischemia -reperfusion protocol. The effects of that molecule were studied biochemically using blood mean albumin levels. 40 rats of mean weight 231.875 g were used in the study. Albumin levels were measured at 60th min of reperfusion (groups A and C) and at 120th min of reperfusion (groups B and D). The drug U-74389G was administered only in groups C and D. U-74389G administration signifi cantly decreased the predicted albumin levels by 3.63% ± 0.87% (p = 0.0001). Reperfusion time non-signifi cantly increased the predicted albumin levels by 0.72% ± 1.04% (p = 0.4103). However, U-74389G administration and reperfusion time together signifi cantly decreased the predicted albumin levels by 2.02% ± 0.54% (p = 0.0005). U-74389G administration whether it interacted or not with reperfusion time has signifi cant decreasing short -term effects on albumin levels. It seems that the antioxidant capacity is associated with albumin catabolism.
INTRODUCTION

P ermanent or transient damage with serious implications on adjacent organs and systems may be due to tissue ischemia -reperfusion (IR).
The use of U-74389G in IR has been a challenge for many years. However, although the progress was signifi cant, several practical questions have not been clarifi ed. They include: a) how potent U-74389G should be; b) when should it be administered; and c) at what optimal dose U-74389G should be administered. The promising effect of U-74389G in tissue protection has been noted in several IR studies. U-74389G or also known as 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-pregna-1,4,9(11)-triene-3,20-dione maleate salt is an antioxidant which prevents both arachidonic acid-induced and iron-dependent lipid peroxidation1. It protects against IR injury in animal organs such as heart, liver and kidney models. These membrane-associated antioxidants are particularly effective in preventing permeability changes in brain microvascular endothelial cells monolayers [2] . A meta-analysis of 20 published seric variables, coming from the same experimental settings, tried to provide a numeric evaluation of the U-74389G effi cacy at the same endpoints (Table 1) . Several publications addressed trials of other similar antioxidant molecules to which the studied molecule U-74389G belongs to.
The aim of this experimental study was to examine the effect of the antioxidant drug "U-74389G" on rat model and particularly in a generalized ischemia -reperfusion (IR) protocol. The effects of that molecule were studied by measuring blood mean albumin levels.
MATERIAL AND METHODS
Animal preparation
This basic experimental research was licensed by Veterinary Address of East Attiki Prefecture under 3693/12-11-2010 & 14/10-1-2012 decisions. All consumables, equipment and substances, were a grant of Experimental Research Centre of ELPEN Pharmaceuticals Co. Inc. S.A. at Pikermi, Attiki. Accepted standards of human animal care were adopted for Albino female Wistar rats. 7 days pre-experimental normal housing included ad libitum diet in laboratory. Prenarcosis of animals preceded of continuous intra-experimental general anesthesia [3] [4] [5] [6] , oxygen supply, electrocardiogram and acidometry. Post-experimental euthanasia did not permitted awakening and preservation of the animals. Rats were randomly delivered to four experimental groups by 10 animals in each one, using following protocols of IR: Ischemia for 45 min followed by reperfusion for 60 min (group A); ischemia for 45 min followed by reperfusion for 120 min (group B); ischemia for 45 min followed by immediate U-74389G intravenous (IV) administration and reperfusion for 60 min (group C); ischemia for 45 min followed by immediate U-74389G IV administration and reperfusion for 120 min (group D). The dose of U-74389G was 10 mg/kg body mass of animals. Ischemia was caused by laparotomic clamping inferior aorta over renal arteries with forceps for 45 min. Reperfusion was induced by removing the clamp and re-establishing inferior aorta patency. U-74389G was administered at the time of reperfusion; through catheterized inferior vena cava. The albumin levels were determined at 60 th min of reperfusion (for A and C groups) and at 120 th min of reperfusion (for B and D groups). Fourty female Wistar albino rats were used (mean weight 231.875 g [Standard Deviation (SD): 36.59703 g], with minimum weight 165 g and maximum weight 320 g. Rats' weight could be potentially a confusing factor, e.g. more obese rats to have higher albumin levels. This assumption was also investigated. 
Control groups
Statistical analysis
Every weight and albumin level group was compared with each other by statistical standard t-tests (Table 3) . Any signifi cant difference among albumin levels, was investigated whether owed in any potent signifi cant weight one. The application of generalized linear models (glm) with dependant variable the albumin levels was followed. The 3 independent variables were the U-74389G or no drug administration, the reperfusion time and both variables in combination. Inserting the rats' weight also as an independent variable at glm analysis, a very signifi cant relation resulted in (p = 0.0206), so as to further investigation was needed. The predicted albumin values, adjusted for rats' weight were calculated and are depicted at table 5. Afterwards, every predicted albumins level group was compared with each other by statistical standard t-tests ( Table 6 ). The application of glm with dependant variable the predicted albumins levels was followed. The 3 independent variables were again the U-74389G or no drug administration, the reperfusion time and both variables in combination. Reviewing the above and table 3, table 4 Results are expressed as Mean ± SD of the mean (*P < 0.05, n = 10)
DISCUSSION
Ischemia may infl uence the albumin levels. Liepinsh E. et al. demonstrated7 that ischemic damage is signifi cantly lower in the fed state compared with fasted state in Wistar and diabetic Goto-Kakizaki rats' hearts. Even overnight fasting could provoke and aggravate cardiovascular events and high-risk cardiovascular patients should avoid prolonged fasting periods. Abubakar S. et al. determined8 the mean serum albumin signifi cantly higher by 45.67% in short-term fi rst-ever acute stroke favourable outcome patients than those with unfavourable outcome (p = 0.0001). Patients that died had signifi cantly lower serum albumin (1.66 g/dl) than survivors (p = 0.0001). Serum albumin of 1.55 g /dL has sensitivity of 100% and specifi city of 61.5%. Low admission serum albumin was an independent determinant of poor outcome. Herisson F. et al. found [9] neither difference nor correlation in admission baseline ischemia-modifi ed albumin (IMA) levels within 4.5 hours of acute ischemic and hemorrhagic stroke onset patients. Consuegra-Sanchez L. et al. found the 30-day combined end point 1.48-fold (p = 0.017) and the 1-year mortality rate 1.78-fold (p = 0.028) signifi cantly10 higher in patients with IMA levels > 93.3 U/ml obtained on admission compared with lower IMA or IMA as a general independent predictor patients presenting to the emergency department with typical acute chest pain. Polk J.D. et al. measured signifi cantly higher cobalt-albumin binding assay (CABA) test values by 1.67-fold in clinically diagnosed [11] intestinal ischemia patients, than control patients without intestinal ischemia (p = 0.0002). This resulted in a sensitivity of 100% and a specifi city of 85.7% for the CABA test, making it a useful tool for risk stratifi cation of intestinal ischemia. Dusek J. et al. used [12] a negative IMA marker as an aid to rule out acute coronary syndrome (ACS) in low risk symptomatic patients with non-diagnostic ECG and normal troponin. Worster A. et al. found likelihood ratios 1.35 and 0.98 for IMA < and > 80 U/mL respectively within 6 hours after chest pain in order to predict [13] a serious cardiac outcome within the following 72 hours, suggesting IMA as a poor short term predictor of serious cardiac outcomes. Rafael Sadaba J. et al. reduced [14] the mean tissue perfusion of the upper limb by 15.38% (p = 0.0005) using Technetium-99m human serum albumin after removal of the radial artery, but did not affect short term hand function. Steinbauer M. et al. enhanced [15] the half-life and antioxidant activity of nitroxides by their covalent binding to human serum albumin, resulting in polynitroxyl albumin (PNA) in an IR hamster dorsal skinfold chamber model. PNA in the dose 1% b.w. and to a lesser extent albumin effectively reduced post-ischemic microvascular perfusion failure, and tissue injury. Although free oxygen radical scavenging seems to be an underlying mechanism leading to the benefi cial effects of PNA on IR injury, hemodilution and known radical scavenging properties of pure albumin contribute in part to the observed effects. Donaldson G.C. et al. explained why deaths from arterial disease are more prevalent in winters associating short-term falls in temperature [16] with signifi cant and prolonged hemoconcentration and hypertension which produce signifi cant increases in serum albumin and in mortalities from ischemic heart disease and cerebrovascular disease. Arend S.M. et al. found [17] similar signifi cant decreases in serum albumin values within 24 h in heart patients both treated and control ones with nitroglycerin. Pollock D.M. et al. produced [18] a signifi cant increase by 2.05-fold nearly identical to those of atrial natriuretic factor (ANF) at 0.5 μg/kg/min in glomerular fi ltration rate (GFR) administering 10 μg/kg/min A68828 after acute renal IR failure compared with vehicle controls (p < 0.05). These results indicate that infusion of a reduced-size analogue of ANF, A68828ANF improves renal function in the immediate post-ischemic period in Sprague-Dawley rats. Tilton R.G. et al. decreased the rate19 of intravascular clearance of radiolabelled albumin by 36% and increased the mean transit time of the coronary vasculature by albumin approximately 1.875-fold in ischemic hearts than control hearts from rabbits fed normal chow and 2-fold increase prior to ischemia in rabbits fed cholesterol for 2-3 weeks.
Also, albumin levels are perhaps infl uenced by U-74389G. Bagetta G. et al. studied20 the epileptogenic and neurodegenerative effects of dendrotoxin K (DTx-K), from Dendroaspis polylepsis, a specifi c blocker of a noninactivating, voltage-sensitive K ± channel, after focal injection into one dorsal hippocampus in rats pretreated with the 21-aminosteriod U-74389G, a scavenger of free oxygen radicals. Administration of 35 pmol DTx-K elicited in all of the treated animals motor seizures and bilateral electrocortical (ECoG) discharges. Quantitation of hippocampal damage after 24 h revealed signifi cant bilateral neuronal cell loss relative to the corresponding brain regions of rats injected with bovine serum albumin (300 ng). Systemic (i.p.) administration of U-74389G (5 mg/kg given 30 min beforehand) delayed the onset of motor and ECoG seizures and reduced the number of epileptogenic discharges typically observed in rats receiving an injection of DTx-K (35 pmol) alone. Similarly, this treatment prevented the damage infl icted to the hippocampus by the toxin. In conclusion, the present data support a role for free oxygen radicals in mediating hippocampal damage induced by DTx-K. Tasaka S. et al. attributed21 hyperoxic lung injury to oxygen radicals produced under hyperoxic conditions. They injected either vehicle or 10 mg/kg of U-74389G 30 min before the 90% O 2 exposure for 48 h and injected the same dose 12, 24, and 36 h later in guinea pigs. They measured the concentration ratio of 125I-labeled albumin in lung tissue and bronchoalveolar lavage (BALF) fl uid compared with plasma (BALF/P and T/P respectively) as indexes of pulmonary endothelial damage.
CONCLUSION
U-74389G administration, whether it interacted or not with reperfusion time, has signifi cant decreasing short -term effects on albumin levels. It is interesting to be investigated how the antioxidant capacity consumes albumins and into which metabolic pathways are involved, by further molecular studies.
